• May 27, 2024

Lucy Submits PMTAs for Modern Oral Products

 Lucy Submits PMTAs for Modern Oral Products
Photo: Lucy Goods

Lucy Goods has submitted premarket tobacco product applications (PMTAs) to the U.S. Food and Drug Administration seeking marketing authorization of 42 of its modern oral nicotine products, including its innovative line of capsule pouches.

Lucy is a developer, marketer and distributor of next-generation nicotine products that offer adult tobacco consumers alternatives to conventional tobacco. One of the key product innovations described in Lucy’s recently submitted PMTAs is its use of nontobacco nicotine.

The nontobacco nicotine in Lucy products is manufactured using principles of green chemistry but is otherwise chemically identical to tobacco-derived nicotine in other modern oral products on the market, according to Lucy Goods. The low-waste manufacturing process does not require arable land or pesticides used in the cultivation of tobacco for tobacco-derived nicotine.

Lucy’s recent filings represent the second round of FDA applications from the company. In 2020, Lucy submitted PMTAs for its modern oral nicotine products containing tobacco-derived nicotine, which are currently under review by the FDA. Even before the FDA was granted regulatory authority over nontobacco nicotine products, the company had been engaged in serious efforts to prepare PMTAs for its suite of nontobacco nicotine products.

Willie McKinney

“Lucy’s commitment to working with the FDA is essential to its goal of delivering innovative nicotine products for switching adult smokers,” said Willie McKinney, CEO of McKinney Regulatory Science Advisors and a regulatory advisor to Lucy, in a statement. “These PMTAs for Lucy’s NTN [nontobacco nicotine] modern oral products demonstrate the company’s ability to drive such innovation responsibly.”

“Submitting PMTAs for our nontobacco nicotine products is a key milestone for us as we continue to create the highest quality and most innovative products in the industry,” stated David Renteln, CEO of Lucy. “We are proud of the evidence we have provided to the FDA in these PMTAs, and we look forward to working with the agency as the process moves forward.”

Lucy is an independently owned and operated nicotine alternative company formed with the mission of reducing tobacco-related harm to zero.